1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin (整合素)

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16143
    Cilengitide TFA Inhibitor 98.84%
    Cilengitide 是有效的,选择性的 αvβ3 和 αvβ5 受体整合素抑制剂,IC50 分别为 4 nM 和 79 nM。
    Cilengitide TFA
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) 99.70%
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) 是一种对 αvβ3 具有高亲和力的环状 RGD 多肽,能够破坏细胞整合素相互作用。Cyclo(Arg-Gly-Asp-D-Phe-Cys) 抑制胚胎干细胞 (ESC) 的多能性基因表达,并在体内抑制 mESC 的致瘤潜力。Cyclo(Arg-Gly-Asp-D-Phe-Cys) 可用于肿瘤相关的研究。
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-134130
    Integrin modulator 1 Agonist 99.44%
    Integrin modulator 1 是一种有效和选择性的 α4β1 整联蛋白激动剂,IC50 值为 9.8 nM。Integrin modulator 1 增加了 α4β1 整联蛋白介导的细胞粘附,EC50 值为 12.9 nM。
    Integrin modulator 1
  • HY-107588
    TC-I 15 Inhibitor 99.80%
    TC-I 15 (TC-I-15) 是一种变构型胶原结合整合素 α2β1 抑制剂,对与 GFOGER 和GLOGEN 结合的 IC50 分别为 26.8 μM 和 0.4 μM。TC-I 15 抑制血小板粘附胶原蛋白和血栓沉积。
    TC-I 15
  • HY-15770
    TR-14035 Antagonist 98.06%
    TR-14035 是一种具有口服活性的 α4β74β1 整合素 (α4β74β1 integrin) 双重抑制剂,对 α4β7 和 α4β1 作用的 IC50 值分别为 7 nM 和 87 nM。TR-14035 可用于炎症和自体免疫疾病的研究。
    TR-14035
  • HY-115677
    ILK-IN-3 Inhibitor 99.62%
    ILK-IN-3 是一种具有口服活性的 整合素连接激酶 (ILK) 抑制剂。ILK-IN-3 提高 Docetaxel (HY-B0011) 在原位 LCC6 模型中的抗癌功效。
    ILK-IN-3
  • HY-P0278A
    RGD Trifluoroacetate 99.75%
    RGD Trifluoroacetate 是一种三肽,能够有效的引起细胞黏着,定位某种特定细胞系并产生特定的细胞反应;RGD Trifluoroacetate 能够与 integrins 结合。
    RGD Trifluoroacetate
  • HY-47888
    PLN-1474 Inhibitor 99.30%
    PLN-1474 (compound 1) 是具有口服活性的,选择性的 ανβ1 整合素抑制剂,IC50 值 <50 nM。PLN-1474 在肝纤维化小鼠模型中显著降低肝脏 pSMAD3/SMAD3 水平、肝脏胶原蛋白基因表达和肝脏 OHP 浓度。PLN-1474 可用于预防、延缓或研究纤维化或肝硬化疾病或紊乱的研究。
    PLN-1474
  • HY-P0023A
    Cyclo(-RGDfK) TFA Inhibitor 99.82%
    Cyclo(-RGDfK) TFA 是一种有效,选择性的整合素 αvβ3 抑制剂,其 IC50 值为 0.94 nM。Cyclo(-RGDfK) TFA 通过与细胞表面 αvβ3 整合素的特异性结合,有效靶向肿瘤微血管和癌细胞。
    Cyclo(-RGDfK) TFA
  • HY-P1740
    RGD peptide (GRGDNP) Inhibitor 99.63%
    RGD peptide (GRGDNP) 是整合素-配体相互作用的抑制剂。RGD peptide (GRGDNP) 竞争性抑制 α5β1 与细胞外基质 (ECM) 的结合。RGD peptide (GRGDNP) 通过激活增强 pro-caspase-3 激活和自动加工的构象变化来促进细胞凋亡。RGD peptide (GRGDNP) 在细胞粘附、迁移、生长和分化中起重要作用。
    RGD peptide (GRGDNP)
  • HY-P0295
    Gly-Arg-Gly-Asp-Ser Inhibitor 99.87%
    Gly-Arg-Gly-Asp-Ser 是一种五肽,构成了糖蛋白,骨桥蛋白与细胞的结合域。
    Gly-Arg-Gly-Asp-Ser
  • HY-110117
    BIRT 377 Inhibitor 98.07%
    BIRT 377是一种能有效抑制细胞间粘附分子-1 (ICAM-1)淋巴细胞功能相关抗原-1 (LFA-1) 相互作用的抑制剂,具有口服生物利用性,Ki 为 25.8 nM。BIRT 377 也能在体内抑制 IL-2 的产生。BIRT 377 可用于炎症与免疫紊乱的研究。
    BIRT 377
  • HY-70073
    Zaurategrast Inhibitor 98.07%
    Zaurategrast (CT7758) 是一种有效的,具有口服活性的 α4-integrin 抑制剂。
    Zaurategrast
  • HY-107587
    A-286982 Inhibitor 99.33%
    A-286982 是一种有效的变构 LFA-1/ICAM-1 相互作用抑制剂,在 LFA-1/ICAM-1 结合和 LFA-1 介导的细胞粘附试验中,IC50 分别为 44 nM 和 35 nM。
    A-286982
  • HY-18676B
    ILK-IN-2 Inhibitor 99.41%
    ILK-IN-2 (OSU-T315 analog) 是一种ILK抑制剂。
    ILK-IN-2
  • HY-U00003
    ICAM-1-IN-1 Inhibitor 99.94%
    ICAM-1-IN-1 是有效,选择性的 E-selectinICAM-1 抑制剂,IC50值分别为7和5 nM。
    ICAM-1-IN-1
  • HY-P0290A
    GRGDSP TFA Inhibitor ≥98.0%
    GRGDSP (TFA) 是一种整联蛋白 (integrin) 抑制剂。
    GRGDSP TFA
  • HY-19344A
    Lifitegrast sodium

    立他司特钠

    Inhibitor 99.33%
    Lifitegrast (SAR 1118) sodium 是一种有效的整合素 (integrin) 拮抗剂。Lifitegrast sodium 阻断细胞间粘附分子1 (ICAM-1) 与淋巴细胞功能相关抗原 (LFA-1) 的结合,中断 T 细胞介导的炎症周期。 Lifitegrast sodium 抑制 Jurkat T 细胞附着于 ICAM-1IC50 为 2.98 nM。Lifitegrast sodium 可用于干眼症的研究。
    Lifitegrast sodium
  • HY-P3448
    Certepetide 99.40%
    Certepetide (CEND-1) 是一种双功能环肽 (a.k.a. iRGD)。Certepetide 是一种可穿透肿瘤的多肽,其 RGD motif 可与 α-V 整联蛋白 (alphav-integrins) 相互作用,并激活神经纤毛蛋白 1 (NRP-1),从而将实体瘤微环境转化为临时活性分子管道。Certepetide 可在肿瘤中累积,可用于胰腺癌和其他实体瘤的研究。
    Certepetide
  • HY-P99183
    Abituzumab Inhibitor 99.38%
    Abituzumab (DI17E6) 是一种人源化抗 integrin αV 单克隆抗体 (IgG2 型)。Abituzumab 能有效减少 FAKAktERK 的磷酸化。Abituzumab 可用于癌症,尤其是前列腺癌的研究。
    Abituzumab
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.